Skip to main content
. 2014 May 27;2(2):397–421. doi: 10.3390/vaccines2020397

Table 1.

Parameter values.

Parameter Definition Value Range Units Reference
rW Virus growth rate for wild-type in the absence of antibodies 23.60 0–46 day 1 Calculated (Appendix A)
rM1 Virus growth rate for first mutant 23.23 0–46 day 1 Calculated (Appendix A)
rM2 Virus growth rate for second mutant 23.09 0–46 day 1 Assumed
K Virus carrying capacity 1.14 × 108 7.47 × 108–3.82 × 108 virus ml 1 Calculated (Appendix A)
pW Wild-type virus neutralization by antibody 1.462 × 102 × m (1.21 × 102–2.67 × 102) × m ml mg 1 day1 Calculated (Appendix A)
pM1 Mutant 1 virus neutralization by antibody (varied) ml mg 1 day1 Assumed
pM2 Mutant 2 virus neutralization by antibody (varied) ml mg 1 day1 Assumed
q Antibody decay rate 0.0315 0.0277–0.0365 day 1 [ 32]
ϵ1 Mutation rate from wild-type to first mutant (per base per cycle) 2.7 × 105 1 × 105–3.4 × 105 day 1 [ 36]
ϵ2 Mutation rate from wild-type to second mutant (per base per cycle) 2.7 × 106 2 × 106–2.7 × 102 day 1 Assumed
Ai Amount of antibody infusion 38.4 × m (25.6–51.2) × m mg ml 1 [ 10 , 11 ]
A0 Antibody on Day 0 37.2 24.9–49.4 mg ml 1 Calculated (Appendix A)
VW(0) Number of wild-type viral particles that initiated infection 224 175–350 virus ml−1 [ 10,37]
VM1(0) Number of Mutant 1 viral particles that initiated infection 9 virus ml−1 [ 10]
VM2(0) Number of Mutant 2 viral particles that initiated infection 1 virus ml−1 Assumed
t1/2 Half-life of virus due to antibody neutralization 1.3 0.7–1.8 day [ 3335]
dW , dM1, dM2 Viral clearance rate 23 9.1–36 day−1 [ 38]
m Antibody magnification factor {1, 10, 50}